Literature DB >> 13198045

Clinical experience with reserpine (serpasil): a controlled study.

H P DUSTAN, R D TAYLOR, A C CORCORAN, I H PAGE.   

Abstract

Entities:  

Keywords:  HYPERTENSION/therapy; RAUWOLFIA

Mesh：

Substances：

Year:  1954        PMID： 13198045     DOI： 10.1111/j.1749-6632.1954.tb45924.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  6 in total

1.  Chlorpromazine, reserpine, and isoniazid treatment in mental disorder; a preliminary communication.

Authors:  J K HEWAT; P W LEACH; R W SIMPSON
Journal:  Br Med J       Date:  1955-11-05

2.  Depressive states during Rauwolfia therapy for arterial hypertension; a report of 30 cases.

Authors:  G LEMIEUX; A DAVIGNON; J GENEST
Journal:  Can Med Assoc J       Date:  1956-04-01       Impact factor: 8.262

3.  Hyperchlorhydria induced by intravenous reserpine; response to various therapeutic agents.

Authors:  E M SCHNEIDER; M L CLARK
Journal:  Am J Dig Dis       Date:  1956-01

4.  [Increase of the glycogen content of the brain and concentration of various enzymes in the brain and intestines of mice after reserpine (serpasil) administration].

Authors:  W ALBRECHT
Journal:  Klin Wochenschr       Date:  1957-06-01

5.  Indian Rauwolfia research led to the evolution of neuropsychopharmacology & the 2000 Nobel Prize (Part I).

Authors:  Prakash N Tandon
Journal:  Indian J Med Res       Date:  2021-07       Impact factor: 2.375

6.  Reserpine methonitrate, a novel quaternary analogue of reserpine augments urinary excretion of VMA and 5-HIAA without affecting HVA in rats.

Authors:  Satyanarayana Sreemantula; Krishna M Boini; Srinivas Nammi
Journal:  BMC Pharmacol       Date:  2004-11-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.